Genetic medicine is entering a transformative phase where therapeutic RNA can potentially correct defective proteins at their source, offering hope for conditions previously considered intractable. This shift represents a fundamental departure from symptomatic management toward addressing root molecular dysfunction in hereditary diseases. Cystic fibrosis exemplifies this opportunity, as the condition stems from mutations in the CFTR gene that produce defective ion channel proteins, leading to thick mucus accumulation and progressive lung damage. Current therapeutic approaches include small molecule modulators that partially restore CFTR function, but these treatments work only for specific mutations and provide incomplete correction. mRNA-based interventions offer a mutation-agnostic strategy by delivering functional CFTR instructions directly to cells, potentially bypassing the underlying genetic defects entirely. Non-viral delivery systems are emerging as particularly promising vehicles for CFTR mRNA, avoiding the safety concerns associated with viral vectors while maintaining therapeutic efficacy. These lipid nanoparticles and other synthetic carriers can protect mRNA during transit and facilitate cellular uptake in lung tissues where CFTR function is most critical. The therapeutic approach represents a significant evolution from traditional gene therapy, as mRNA provides temporary protein expression without permanently altering cellular DNA. This safety profile could accelerate clinical adoption while still delivering meaningful therapeutic benefit. Early clinical trials are evaluating both replacement mRNA strategies and innovative editing approaches that could correct CFTR defects at the transcript level. The mutation-independent nature of mRNA therapy could democratize treatment access for the diverse array of CFTR mutations that cause cystic fibrosis, potentially offering benefit regardless of specific genetic variant.